Research Studies

SGLT2 inhibitor use as an adjunct-to-insulin therapy in patients with T1D has been limited due to the risk of DKA. Patient input is critical to understand how and when the use of these therapies is perceived to be acceptable. We hypothesize that many patients will prefer to take SGLT2 inhibitors even with some modest increase in the risk of DKA. To test this hypothesis we will use a discrete-choice experiment (DCE) to quantify preference towards treatment options.

The purpose of this study is to evaluate the safety, tolerability, and efficacy of an investigational islet cell infusion in individuals aged 18 to 65 with type 1 diabetes with severe low blood sugar (hypoglycemia) and impaired hypoglycemic awareness. The goal of this infusion is to provide replacement cells for the ones that have been lost or do not work properly in people with diabetes. For more information, please respond to this ad and the study team will reach out to you.

Contemporary treatment of types 2 diabetes regularly involves the use of SGLT2 inhibitors. There is now interest in using this medication for type 1 diabetes alongside insulin treatment. T1D patient input is critical in understanding how and when the use of SGLT2 inhibitors is considered acceptable. We wish to explore the thoughts and perspectives of T1D patients about all the factors they would need to consider before starting this medication, including any risks or benefits they anticipate.

Pathway to Prevention screening is the first step for all TrialNet prevention studies. Screening is offered at no cost to eligible individuals to evaluate their personal risk of developing type 1 diabetes (T1D). This unique screening can identify the early stages of T1D years before any symptoms appear. It also helps researchers learn more about how T1D develops and plan new studies exploring ways to prevent it. Screening is offered to family members of people with T1D.

This study compares aerobic exercise training performed before breakfast (i.e., in the fasted state) to similar training performed after breakfast in people with type 1 diabetes. Training will take place over 12 weeks in the Physical Activity Diabetes Lab at the Alberta Diabetes Institute.

The purpose of this study is to explore experiences with virtual care. We are asking people that have gestational diabetes (GDM) to share their thoughts and experience in a focus group. We are recruiting individuals who pregnancy received care in Alberta. The study results will help us determine if there are differences between in-person and virtual care for GDM management, informing us how to improve GDM care in the future.

Artificial sweeteners (like sucralose) are popular low-calorie sugar substitutes, especially among patients with diabetes, but do they really help with blood sugar control? Research so far has shown mixed results. That’s why we’re launching a new study focused on patients with type 1 diabetes (T1D) to understand better how these sweeteners affect the body.